Clinically significant pharmacokinetic drug interactions with psychoactive drugs: Antidepressants and antipsychotics and the cytochrome P450 system

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 1, 1999, Pages 7-16

  Tanaka, E ^a   Hisawa, S ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADVERSE DRUG REACTION; ANXIETY NEUROSIS; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENOTYPE; PRESCRIPTION; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; MENTAL DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032905234     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00200.x     Document Type: Review

References (108)

1. 1. Guengerich FP. (1992) Characterization of human cytochrome P450 enzymes. FASEB Journal, 6, 745-748.
2. 2. Nakamura K, Goto F, Ray WA, et al. (1985) Interethinic differences in genetic polymorphism of debrisoquin and mepheytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 38, 402-408.
3. 3. Wilkinson GR, Guengerich FP, Branch RA. (1989) Genetic polymorphism of S-mepheytoin hydroxylation. Pharmacology and Therapeutics, 43, 53-76.
4. 4. Bertilsson L, Lou YQ, Du YL, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mepheytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
5. 5. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. (1993) Isolation and characterization of human liver cytochrome P450:2C19: correlation between 2C19 and S-mepheytoin hydroxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
6. 6. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. European Journal of Clinical Pharmacology, 39, 533-537.
7. 7. Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586.
8. 8. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183-187.
9. 9. Brøsen K, Gram LF. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537-547.
10. 10. Meyer UA, Skoda RC, Zanger UM. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. Pharmacology and Therapeutics, 46, 297-308.
11. 11. Eichelbaum M, Gross AS. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
12. 12. Lennard MS. (1990) Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacology and Toxicology, 67, 273-283.
13. 13. Gonzalez FK, Meyer UA. (1991) Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics, 50, 233-238.
14. 14. Bertilsson L. (1995) Geographical/interracial diffeences in polymorphic drug oxidation. Clinical Pharmacokinetics, 29, 192-209.
15. 15. Ereshefsky L, Riesenman C, Lam YWF. (1995) Antidepressant drug interactions and the cytochrome P450: system: the role of cytochrome P4502D6. Clinical Pharmacokinetics, 29(Suppl. 1), 10-19.
16. 16. Brosen K. (1995) Drug interactions and the cytochrome P450: system: the role of cytochrome P4501A2. Clinical Pharmacokinetics, 29(Suppl. 1), 20-25.
17. 17. Flockhart DA. (1995) Drug interactions and the cytochrome P450: system: the role of cytochrome P450:2C19. Clinical Pharmacokinetics, 29(Suppl. 1), 10-19.
18. 18. Tanaka E. (1999) Pharmacokinetic drug interactions of clinical significance with benzodiazepines. Journal of Clinical Pharmacy and Therapeutics.
19. 19. Olesen OV, Linnet K. (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metabolism and Disposition, 25, 740-744.
20. 20. Madsen H, Rasmussen BB, Brosen K. (1977) Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clinical Pharmacology and Therapeutics, 61, 319-324.
21. 21. Morinobu S, Tanaka T, Kawakatsu S, et al. (1997) Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry & Clinical Neurosciences, 51, 253-257.
22. 22. Koyama E, Sohn DR, Shin SG, et al. (1994) Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4-hydroxylation phenotypes. Journal of Pharmacology and Experimental Therapeutics, 271, 860-867.
23. 23. Koyama E, Tanaka T, Chiba K, et al. (1996) Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4-hydroxylation status in Japanese depressive patients. Journal of Clinical Psychopharmacology, 16, 286-293.
24. 24. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. (1997) Cytochromes P450 mediating the N-demethylation of amitriptyline. British Journal of Clinical Pharmacology, 43, 137-144.
25. 25. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. (1998) Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP2C19 and 3A4. Journal of Clinical Pharmacology, 38, 112-121.
26. 26. Nielsen KK, Flinois JP, Beaune P, Brosen K. (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. Journal of Pharmacology and Experimental Therapeutics, 277, 1659-1664.
27. 27. Ball SE, Ahern D, Scatina J, Kao J. (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology, 43, 619-626.
28. 28. Koyama E, Chiba K, Tani M, Ishizaki T. (1996) Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. Journal of Pharmacology and Experimental Therapeutics, 278, 21-30.
29. 29. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. (1997) Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatrica Scandinavica, 96, 379-384.
30. 30. Muralidharan G, Cooper JK, Hawes EM, Korchinski ED, Midha KK. (1996) Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. European Journal of Clinical Pharmacology, 50, 121-128.
31. 31. Bagli M, Hoflich G, Rao ML, et al. (1995) Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. International Journal of Clinical Pharmacology and Therapeutics, 33, 646-652.
32. 32. Fang J, Baker GB, Silverstone PH, Coutts RT. (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular and Molecular Neurobiology, 17, 227-233.
33. 33. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. (1997) Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. British Journal of Clinical Pharmacology, 44, 557-564.
34. 34. Tyndale RF, Kalow W, Inaba T. (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450:IID6 (sparteine/debrisoquine mono-oxygenase). British Journal of Clinical Pharmacology, 31, 655-660.
35. 35. Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Therapeutic Drug Monitoring, 14, 92-97.
36. 36. Llerena A, Cobaleda J, Martinez C, Benitez J. (1996) Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. European Journal of Drug Metabolism and Pharmacokinetics, 21, 129-138.
37. 37. Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L. (1989) Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clinical Pharmacology and Therapeutics, 46, 78-81.
38. 38. von Bahr C, Movin C, Nordin C, et al. (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 49, 234-240.
39. 39. Meyer JW, Woggon B, Baumann P, Meyer UA. (1990) Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. European Journal of Clinical Pharmacology, 39, 613-614.
40. 40. Ereshefsky L, Riesenman C, Lam YW. (1996) Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Journal of Clinical Psychiatry, 57(Suppl. 8), 17-24.
41. 41. Nemeroff CB, DeVane CL, Pollock BG. (1996) Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153, 311-320.
42. 42. Mitchell PB. (1997) Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety, 17, 390-406.
43. 43. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics, 33, 454-471.
44. 44. Baker GB, Fang J, Sinha S, Coutts RT. (1998) Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neuroscience and Biobehavioral Reviews, 22, 325-333.
45. 45. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. (1994) The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical Pharmacology and Therapeutics, 62, 145-156.
46. 46. Vaughan DA. (1988) Interaction of fluoxetine with tricyclic antidepressants. American Journal of Psychiatry, 145 , 1478.
47. 47. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. European Journal of Clinical Pharmacology, 40, 119-120.
48. 48. Bergstrom RF, Peyton AL, Lemberger L. (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapeutics, 51, 239-248.
49. 49. Gram LF, Hansen MG, Sindrup SH, et al. (1993) Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Therapeutic Drug Monitoring, 15, 18-24.
50. 50. Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. (1993) Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. International Journal of Clinical Pharmacology Research, 13, 167-171.
51. 51. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology, 44, 349-355.
52. 52. Lydiard RB, Anton RF, Cunningham T. (1993) Interactions between sertraline and tricyclic antidepressants. American Journal of Psychiatry, 150, 1125-1126.
53. 53. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology, 14, 90-98.
54. 54. Seifritz E, Holsboer-Trachsler E, Hemmeter U, Eap CB, Baumann P. (1994) Increased trimipramine plasma levels during fluvoxamine comedication. European Neuropsychopharmacology, 4, 15-20.
55. 55. Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. (1996) Paroxetine shifts imipramine metabolism. Psychiatry Research, 59, 189-196.
56. 56. Fleishaker JC, Hulst LK. (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology, 46, 35-39.
57. 57. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. (1992) Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics, 52, 479-486.
58. 58. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. (1991) Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology, 104, 323-327.
59. 59. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
60. 60. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychopharmacology, 15, 125-131.
61. 61. Perucca E, Gatti G, Cipolla G, et al. (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clinical Pharmacology and Therapeutics, 56, 471-476.
62. 62. Gardner MJ, Baris BA, Wilner KD, Preskorn SH. (1997) Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clinical Pharmacokinetics, 32(Suppl. 1), 43-49.
63. 63. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics, 43, 412-419.
64. 64. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. (1989) Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatrica Scandinavica, Supplementum, 350, 102-106.
65. 65. van Harten J, Holland RL, Wesnes K. (1992) Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepine bromazepam and lorazepam: a randomized, cross-over study. European Neuropsychopharmacology (Abstract), 2, 381.
66. 66. Ring BJ, Binkley SN, Roskos L, Wrighton SA. (1995) Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1-hydroxy midazolam formation in vitro. Journal of Pharmacology and Experimental Therapeutics, 275, 1131-1135.
67. 67. Pearson HJ. (1990) Interaction of fluoxetine with carbamazepine. Journal of Clinical Psychiatry, 51, 126.
68. 68. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. (1991) Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical Pharmacology and Therapeutics, 50, 10-15.
69. 69. Shader RI, Greenblatt DJ, von Moltke LL. (1994) Fluoxetine inhibition of phenytoin metabolism. Journal of Clinical Psychopharmacology, 14, 375-376.
70. 70a. Fritze J, Unsorg B, Lanczik M. (1991) Interaction between carbamazepine and fluvoxamine. Acta Psychiatrica Scandinavica, 84, 583-584.
71. 70b. Joblin M. (1994) Possible interaction of sertraline with carbamazepine. New Zealand Medical Journal, 107, 43.
72. 71. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K. (1996) Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Journal of Clinical Psychiatry, 57(Suppl. 1), 24-28.
73. 72. Bertilsson L, Carrillo JA, Dahl ML, et al. (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology, 38, 471-473.
74. 73. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. (1991) Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. American Journal of Psychiatry, 148, 790-792.
75. 74. Daniel DG, Randolph C, Jaskiw G, et al. (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. Journal of Clinical Psychopharmacology, 14, 340-343.
76. 75. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16, 368-374.
77. 76. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. Journal of Clinical Psychopharmacology, 14, 279-281.
78. 77. DuMortier G, Lochu A, Colen de Melo P, et al. (1996) Elevated clozapine plasma concentrations after fluvoxamine initiation. American Journal of Psychiatry, 153, 738-739.
79. 78. Centorrino F, Baldessarini RJ, Kando J, et al. (1994) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry, 151, 123-125.
80. 79. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. American Journal of Psychiatry, 153, 820-822.
81. 80. Woolfrey S, Gammack NS, Dewar MS, Brown PJ. (1993) Fluoxetine-warfarin interaction. British Medical Journal, 307, 241.
82. 81. Hanger HC, Thomas F. (1995) Fluoxetine and warfarin interactions. New Zealand Medical Journal, 108, 157.
83. 82. Apseloff G, Wilner KD, Gerber N, Tremaine LM. (1997) Effect of sertraline on protein binding of warfarin. Clinical Pharmacokinetics, 32(Suppl. 1), 37-42.
84. 83. Sperber AD. (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety, 6, 460-462.
85. 84. van Harten J. (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 24, 203-220.
86. 85. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. (1997) Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Therapeutic Drug Monitoring, 19, 56-62.
87. 86. Swims MP. (1993) Potential terfenadine-fluoxetine interaction. Annals of Pharmacotherapy, 27, 1404-1405.
88. 87. Marchiando RJ, Cook MD, Jue SG. (1995) Probable terfenadine-fluoxetine-associated cardiac toxicity. Annals of Pharmacotherapy, 29, 937-938.
89. 88. Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E. (1997) Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. British Journal of Clinical Pharmacology, 43, 315-318.
90. 89. Antal EJ, Ereshefsky L, Wells B, et al. (1986) Multicenter evaluation of the kinetic and clinical interaction of alprazolam and imipramine. Clinical Pharmacology and Therapeutics, 39, 178.
91. 90. Avenoso A, Spina E, Campo G, et al. (1997) Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacological Research, 35, 335-339.
92. 91. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. (1992) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Therapeutic Drug Monitoring, 14, 261-264.
93. 92. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. (1997) Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clinical Pharmacology and Therapeutics, 62, 334-347.
94. 93. Cooper SF, Dugal R, Elie R, Albert JM. (1979) Metabolic interaction between amitriptyline and perphenazine in psychiatric patients. Progress in Neuro-Psychopharmacology, 3, 369-376.
95. 94. Vandel B, Vandel S, Allers G, Bechtel P, Volmat R. (1979) Interaction between amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology, 65, 187-190.
96. 95. Nelson JC, Jatlow PI. (1980) Neuroloeptic effect on desipramine steady-state plasma concentrations. American Journal of Psychiatry, 137, 1232-1234.
97. 96. Loga S, Curry S, Lader M. (1981) Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clinical Pharmacokinetics, 6, 454-462.
98. 97. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. (1995) The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clinical Neuropharmacology, 18, 233-236.
99. 98. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16, 368-374.
100. 99. Tiihonen J, Vartiainen H, Hakola P. (1995) Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry, 28, 26-28.
101. 100. Linnoila M, Viukari M, Vaisanen K, Auvinen J. (Year?) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry, 137, 819-821.
102. 101. Markowitz JS, Wells BG, Carson WH. (1995) Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy, 29, 603-609.
103. 102. Ereshefsky L, Riesenman C, Lam YWF. (1995) Antidepressant drug interactions and the cytochrome P450 system. Clinical Pharmacokinetics, 29(Suppl. 1), 10-19.
104. 103. Taylor D, Malclmlader. (1996) Cytochromes and psychotropic drug interactions. British Journal of Psychiatry, 168, 529-532.
105. 104. Shen WW. (1997) The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biological Psychiatry, 41, 814-826.
106. 105. Beltilsson L, Dahl ML, Tybring G. (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatrica Scandinavica, 96(Suppl. 391), 14-21.
107. 106. Caccia S. (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clinical Pharmacokinetics, 34, 281-302.
108. 107. Jefferson JW. (1998) Drug interactions - friend or foe? . Journal of Clinical Psychiatry, 59(Suppl. 4), 37-47.